Clinical-stage biotechnology company developing nanobody-based therapeutics for infectious diseases
ExeVir Bio has raised €25M across 1 funding round from 1 investor, most recently a Debt round in Jan 2023. Based in Belgium; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-01-09 | Debt | €25M |
| European Investment Bank |
| View deal → |
